Top companies

ASIANPAINT - 2494.5 (0.55%) AXISBANK - 1126 (0.43%) BAJAJFINSV - 2060 (-0.98%) BAJFINANCE - 1009.45 (0.62%) BHARTIARTL - 1940.5 (0.05%) BPCL - 323.4 (1.62%) COALINDIA - 399.5 (0.93%) HDFCBANK - 967 (0.02%) HEROMOTOCO - 5350 (0.64%) HINDUNILVR - 2574 (-0.27%) ICICIBANK - 1417.2 (-0.31%) INDUSINDBK - 739.95 (-0.31%) ITC - 410.05 (-0.74%) KOTAKBANK - 2051 (1.45%) MARUTI - 15790 (1.39%) ONGC - 236.87 (0.76%) RELIANCE - 1413 (0.55%) SBIN - 856.9 (3.05%) TATAMOTORS - 719 (0.81%) TATASTEEL - 171 (-0.59%) TCS - 3175 (0.93%) TITAN - 3524.6 (-0.91%) WIPRO - 254.17 (0.06%)
TRENDING #BANK NIFTY 149 #ADANIPORTS 86 #ZOMATO 72
Growmudra
Sector: Healthcare

Cipla Limited


1560   1 (0.06%)

As on 18 Sep, 2025 08:25 IST
Open 1556
LTP 1560
Previous Close 1559
Day High 1562.5
Day Low 1549.1
Volume 785713

Peers

Company Name Price Change %Change Day High Day Low Prev.Close Volume
Sun Pharmaceutical Industries Limited 0 0 0 0 0 0 0
Dr. Reddy's Laboratories Limited 0 0 0 0 0 0 0
Divi's Laboratories Limited 0 0 0 0 0 0 0
Growmudra

Top Gainers

Company LTP Change Gain
SBIN 856.9 25.35 3.05 %
BPCL 323.4 5.15 1.62 %
KOTAKBANK 2051 29.3 1.45 %
MARUTI 15790 217 1.39 %
COALINDIA 399.5 3.7 0.93 %

Top Losers

Company LTP Change Loss
BAJAJFINSV 2060 -20.3 -20.3 %
TITAN 3524.6 -32.2 -32.2 %
ITC 410.05 -3.05 -3.05 %
TATASTEEL 171 -1.02 -1.02 %
INDUSINDBK 739.95 -2.3 -2.3 %
Growmudra

Latest News


By Debdeep Gupta  |  26 Aug, 2025

Trade Spotlight: How should you trade TCS, Exide Industries, Cipla, Max Financial Services, Hyundai Motor India, Nykaa, and others on August 26?

The benchmark indices rebounded 0.4 percent on August 25 after nearly a percent loss in the previous session, but the market breadth remained weak. About 1,493 shares declined compared to 1,298 advancing shares on the NSE. The market is likely to consolidate further until it decisively gets back above last Thursday's high. Below are some short-term trading ideas to consider:Mehul Kothari, AVP - Te...


By Debdeep Gupta  |  22 Aug, 2025

Trade Spotlight: How should you trade DMart, Can Fin Homes, Radico Khaitan, Cipla, Dr Reddys Labs, Caplin Point, Afcons Infra, and others on August 22?

Bulls continued to hold the fort despite pressure from bears, helping the Nifty 50 close 0.13 percent higher on August 21, while the market breadth was nearly balanced. Around 1,381 shares declined compared to 1,350 advancing shares on the NSE. Overall, the trend remains favourable for bulls, despite the likelihood of intermittent consolidation. Below are some short-term trading ideas to consider:...


By Debdeep Gupta  |  29 Jul, 2025

Trade Spotlight: How should you trade TCS, Cipla, Torrent Pharma, NCC, Paytm, SBI Life Insurance, UPL, Syrma SGS Technology and others on July 29?

Equity benchmarks started off the monthly F&O expiry week on a negative note, with the Nifty 50 declining 0.63 percent, extending its downward journey for the third straight session on July 28. The market breadth continued to be dominated by bears, with 2,043 shares declining compared to 673 advancing on the NSE. The market may continue to consolidate with a negative bias in the upcoming sessions....


By Debdeep Gupta  |  28 Jul, 2025

Trade Spotlight: How should you trade Eternal, Cipla, Shyam Metalics, Torrent Pharma, Hubtown, Vimta Labs and others on July 28?

The benchmark indices extended their downward move for the second consecutive session, falling 0.9 percent on July 25, with market breadth largely favouring the bears. A total of 2,179 shares were under pressure, compared to just 475 advancing shares on the NSE. The market is expected to consolidate further as long as the frontline indices continue trading below their medium-term moving averages. ...


By Debdeep Gupta  |  17 Apr, 2025

Pharma Q4 preview: Lupin, Sun Pharma, Cipla among top sectoral picks across brokerages

Although Trump's pharma sector tariffs are threatening to hit the sector, and different estimates of the possible impact, analysts across brokerages are keeping their expectations steady for earnings following estimations of muted Q4 FY2025 performance. Estimates reveal a subtle revenue growth, margin improvement and strong US generics performance to support earnings beyond a muted Q4 FY2025 perfo...


Growmudra © 2025 all right reserved

Partner With Us